Review Article
The Metabolic Syndrome and Risk of Chronic Kidney Disease: Pathophysiology and Intervention Strategies
| | Parameters | WHO (1998) | NCEP ATP3 (2001) | IDF (2005) |
| | Required | Insulin resistance in the top 25%; glucose | | Waist >94 cm (men) or 80 cm (women) |
| | Number of abnormalities | >2 | >3 | >2 |
| | Glucose | >6.1 mmol/L (110 mg/dL); 2-hour glucose >7.8 mmol/L (140 mg/dL) | >5.6 mmol/L (100 mg/dL) or drug treatment for elevated blood glucose | >5.6 mmol/L or diagnosed diabetes |
| | HDL cholesterol | <0.9 mmol/L (35 mg/dL) (men); <1.0 mmol/L (40 mg/dL) (women) | <1.0 mmol/L men (40 mg/dL) (men); <1.3 mmol/L (50 mg/dL) (women) or drug treatment for low HDL-C | <1.0 mmol/L (40 mg/dL) (men); <1.3 mmol/L (50 mg/dL) (women) or drug treatment for low HDL-C |
| | Triglycerides | ≥1.7 mmol/L (150 mg/dL) | ≥1.7 mmol/L (150 mg/dL) or drug treatment for elevated triglycerides | ≥1.7 mmol/L (150 mg/dL) or drug treatment for elevated triglycerides |
| | Obesity | Waist/hip ratio >0.9 (men) or >0.85 (women) or BMI ≥30 kg/m2 | Waist ≥102 cm (men) or ≥88 cm (women) | Waist ≥94 cm (men) or ≥80 cm (women) |
| | Hypertension | ≥140/90 mmHg | ≥130/85 mmHg or drug treatment for HTN | ≥130/85 mmHg or drug treatment for HTN |
|
|
